Read's to-do list is already full

Just a few days into the reign of Pfizer's ($PFE) new chief executive Ian Read (photo), several events are creating challenges to the pharmaceutical giant's aim to quickly expand in fast-growing emerging markets--an area it is counting on to help offset the loss of its top-selling product. Report | Article

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.